Reuters: Regulatory News: UPDATE 1-Mylan settles patent suit with Dainippon Sumitomo unit

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

UPDATE 1-Mylan settles patent suit with Dainippon Sumitomo unit May 29th 2012, 13:12 Tue May 29, 2012 9:12am EDT May 29 (Reuters) - Mylan Inc settled a patent lawsuit with a unit of Dainippon Sumitomo Pharma Co, allowing the U.S. drug maker to continue selling a generic version of the Japanese company's drug for breathing difficulty. Mylan can continue selling concentrated Levalbuterol Hydrochloride inhalation solution, a generic version of Sunovion's Xopenex. Mylan will also be able to sell a non-concentrated version upon getting approval from the U.S. Food and Drug Administration, the U.S. company said. The drug is used to ease breathing difficulties faced by ashtma patients and others. Financial details of the agreement were not disclosed. The settlement will dismiss all related litigation between the two companies and Mylan will not have to pay a $18 million damage awarded to Sunovion. Last week, Mylan settled another lawsuit with Sunovion for the Japanese drugmaker's bronchitis medicine Brovana. [ID: nL4E8GOBQN]

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions